Search

Search results

410 results found

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.

Thaçi, Diamant, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, et al. 2023. “Safety and Efficacy of Bimekizumab through 2 Years in Patients With Moderate-to-Severe Plaque Psoriasis: Longer-Term Results from the BE SURE Randomized Controlled Trial and the Open-Label Extension from the BE BRIGHT Trial.”. The British Journal of Dermatology 188 (1): 22-31.